



**DATE:** September 30, 2026  
**TO:** Commonwealth of Kentucky Medicaid Prescriber Network  
**FROM:** MedImpact Healthcare Systems

**Subject: FDA Class I Recall of Thyroid Tablets USP 30 mg (Vitruvias Therapeutics)**

**Status:** The U.S. Food and Drug Administration (FDA) has classified a recall of one lot of Thyroid Tablets USP 30 mg manufactured by Vitruvias Therapeutics, Inc. as a Class I recall, the FDA's most serious recall classification. A Class I recall is issued when there is a reasonable probability that use of, or exposure to, a violative product could cause serious adverse health consequences or death.

The affected product information is provided below.

| Product                   | NDC          | Lot Number | Expiration Date    |
|---------------------------|--------------|------------|--------------------|
| Thyroid Tablets USP 30 mg | 69680-166-00 | 504950     | September 30, 2026 |

Lot 504950 was distributed nationwide between January 31, 2025, and September 30, 2025.

The recall was initiated because the affected tablets may be superpotent, meaning they may contain more thyroid hormone than specified on the product label.

Vitruvias Therapeutics is notifying wholesalers and distributors to discontinue distribution of the affected lot and arrange for its destruction. Patients currently taking Thyroid Tablets USP 30 mg from Lot 504950 should not discontinue therapy without first consulting their healthcare provider regarding appropriate treatment alternatives.

**Providers should:**

- Review patient records to identify individuals who may have received the recalled lot.
- Advise affected patients to contact their pharmacy to determine whether their medication is part of the recalled lot.
- Monitor patients for signs and symptoms of excessive thyroid hormone exposure.
- Consider appropriate clinical management and replacement therapy, as clinically indicated.
- Report adverse events associated with this product to the FDA MedWatch program.
- Refer to the FDA recall announcement or contact the manufacturer for additional information.



Consumers with questions regarding the recall may contact Vitruvias Therapeutics, Inc. at [safety@vitruvias.com](mailto:safety@vitruvias.com) or (256) 239-9373, Monday through Friday, 9:00 a.m. to 5:00 p.m. CT. Patients experiencing adverse effects related to this product should contact their healthcare provider.

## Reporting Adverse Events

Patients are encouraged to report adverse events or side effects related to the use of this product to FDA's MedWatch Safety Information and Adverse Event Reporting Program at 1-800-332-1088 or online at [www.fda.gov/MedWatch/report.htm](http://www.fda.gov/MedWatch/report.htm).

Additional information is available at: <https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/vitruvias-therapeutics-inc-issues-nationwide-recall-one-lot-thyroid-tablets-usp-30-mg-due-potential>

For additional questions, please contact the Kentucky MedImpact team at [KYMFFS@medimpact.com](mailto:KYMFFS@medimpact.com) for Fee-for-Service members or [KYMCOPBM@medimpact.com](mailto:KYMCOPBM@medimpact.com) for Managed Care Organization (MCO) members.

### **KY MCO Contact Information**

|                                           |                                                                                 |
|-------------------------------------------|---------------------------------------------------------------------------------|
| Program Questions                         | <a href="mailto:KYMCOPBM@MedImpact.com">KYMCOPBM@MedImpact.com</a>              |
| Pharmacy Help Desk                        | (800) 210-7628 [24 hours per day/ 7 days per week]                              |
| Prior Authorizations                      | Phone (844) 336-2676 [8:00AM - 7:00PM EST/ 7 days per week]; Fax (858) 357-2612 |
| Pharmacy Portal                           | <a href="https://kyportal.medimpact.com/">https://kyportal.medimpact.com/</a>   |
| BIN: 023880 / PCN: KYPROD1 / GROUP: KYM01 |                                                                                 |

### **KY FFS Contact Information**

|                                           |                                                                                   |
|-------------------------------------------|-----------------------------------------------------------------------------------|
| Program Questions                         | <a href="mailto:KYMFFS@MedImpact.com">KYMFFS@MedImpact.com</a>                    |
| Pharmacy Help Desk                        | (877) 403-6034 [24 hours per day/ 7 days per week]                                |
| Prior Authorizations                      | Phone (877) 403-6034 [8:00AM - 7:00PM EST/ 7 days per week]<br>Fax (858) 357-2612 |
| Pharmacy Portal                           | <a href="https://kyportal.medimpact.com/">https://kyportal.medimpact.com/</a>     |
| BIN: 026309 / PCN: KYPROD1 / GROUP: KYF01 |                                                                                   |